Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.54 +0.54 (+0.98%)
Streaming Delayed Price Updated: 3:41 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
33 34 Next >
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
Could CRISPR Therapeutics be the next big healthcare stock? 
Via The Motley Fool
CRISPR Stock: Bull vs. Bear
CRISPR's first approved product may be right around the corner. 
Via The Motley Fool
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
Why Bluebird Bio Shares Are Plunging Today
 
Via Benzinga
Could This Stock Become the Tesla of Its Industry?
It's in a race to a multi-billion dollar market. 
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics
 
Via Benzinga
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
 
Via Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?
Vertex shares are on the rise. 
Via The Motley Fool
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 10 Best Stocks to Buy in April 2023
Here are 10 stocks to buy now that could unlock explosive gains in your growth-stock portfolio. 
Via The Motley Fool
Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics
Together, the companies could produce a game-changing product. 
Via The Motley Fool
5 Bargain-Basement Stocks to Buy Right Now
Down markets offer us something very positive: deals on quality companies. 
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Moderna?
Both companies use cutting-edge technology. 
Via The Motley Fool
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Your stock screening and research process will never be the same. 
Via The Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
If the stock market continues to rally, this biotech could benefit. 
Via The Motley Fool
Thinking of Buying Biotech Stocks? Do These 3 Things First
It's better to plan ahead than to get caught by surprise. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time
For investors betting on healthcare, look for these three companies to provide the treatments of tomorrow. 
Via InvestorPlace
3 Beaten-Down Stocks That Could Soar This Year
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
These companies have what it takes to grow their revenues -- and their share prices -- over time. 
Via The Motley Fool
If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today
The stock has been on a wild ride over the past few years. 
Via The Motley Fool
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
Get in on CRISPR Therapeutics before it gets expensive. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.